Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Modulation of mRNA Activity Regulates Thrombin Synthesis

By LabMedica International staff writers
Posted on 23 Feb 2011
A paper described the molecular mechanism that regulates synthesis of thrombin, a protein required for blood clotting but also implicated in processes related to inflammation and tumor metastasis.

Thrombin is a key protease involved in blood coagulation, complement activation, inflammation, angiogenesis, and tumor invasion. More...
While prothrombin production increases when an organism experiences stress, the molecular pathways controlling this process have not been defined. Now, in a paper published in the February 4, 2011, issue of the journal Molecular Cell, investigators at the European Molecular Biology Laboratory (Heidelberg, Germany) have found that prothrombin expression is regulated by a posttranscriptional regulatory mechanism responding to stress and inflammation.

This mechanism is triggered by external stimuli that activate p38 MAPK (p38 mitogen-activated protein kinase), one of the class of mitogen-activated protein kinases that are responsive to stress stimuli, such as cytokines, ultraviolet irradiation, heat shock, and osmotic shock, and are involved in cell differentiation and apoptosis.

The activated p38 MAPK stimulates enzymes responsible for manipulating the 3′ end of certain classes of mRNA and phosphorylates the RNA-binding proteins FBP2 and FBP3, which inhibit 3′ end processing of mRNAs. By blocking this inhibitor, p38 MAPK removes an obstacle to thrombin synthesis, and the level of thrombin in the blood increases.

While elevated thrombin production is beneficial to an organism under stress, analysis of liver samples taken from septicemic mice and from cancer patients, revealed that thrombin production increased in response both to widespread inflammation during septicemia and to localized inflammation at the tumor's invasion front.

"Knowing the exact molecules involved, and how they act, has implications for treatment, especially as drugs that inhibit p38 MAPK are already being tested in clinical studies for other conditions,” said contributing author Dr. Matthias Hentze, associate director of the European Molecular Biology Laboratory. Those drugs could be good candidates for potential cancer or septicemia therapies.”

Related Links:

European Molecular Biology Laboratory




Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.